Bone Biologics Corporatio... (BBLG)
NASDAQ: BBLG
· Real-Time Price · USD
2.44
-0.41 (-14.39%)
At close: Sep 05, 2025, 11:33 AM
-14.39% (1D)
| Bid | 2.07 |
| Market Cap | 3.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.22M |
| EPS (ttm) | -21.39 |
| PE Ratio (ttm) | -0.11 |
| Forward PE | -1.2 |
| Analyst | n/a |
| Ask | 3 |
| Volume | 1,220,045 |
| Avg. Volume (20D) | 2,460,993 |
| Open | 2.87 |
| Previous Close | 2.85 |
| Day's Range | 2.35 - 2.87 |
| 52-Week Range | 2.03 - 16.50 |
| Beta | 1.30 |
About BBLG
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BBLG
Website n/a
1 day ago
+37.68%
Bone Biologics shares are trading higher after the...
Unlock content with
Pro Subscription
2 months ago
+10.1%
Bone Biologics shares are trading higher after the compnay announced it filed a USPTO patent for rhNELL-1.
2 months ago · businesswire.com
Bone Biologics Announces Closing of $5.0 Million Public OfferingBURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
2 months ago · businesswire.com
Bone Biologics Announces Pricing of $5.0 Million Public OfferingBURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
2 months ago · businesswire.com
Bone Biologics Regains Compliance with Nasdaq Continued Listing RequirementsBURLINGTON, Mass.--(BUSINESS WIRE)--Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announce...
